Introduction
============

Cancer remains a worldwide medical problem, and has seriously threatened human health. In 2016, there were \~1.7 million new cancer cases in the USA, and about 0.6 million cancer-related deaths.[@b1-cmar-11-1881] Although the number of cancer survivors are increasing because of early diagnosis and treatment, traditional diagnostic and therapeutic approaches still cannot control cancer progression and development.[@b2-cmar-11-1881] Thus, further evidence-based resources for cancer diagnosis are needed so that cancer patients' prognoses can be determined early and precisely.

Chemokines are a class of small molecule proteins that bind to the corresponding cell surface receptors and participate in a variety of physiological, pathological, and immunological processes. Nearly 50 genes in humans encode chemokine ligands and \>20 corresponding chemokine receptors. Chemokines can be divided into four categories based on structural differences: CXC, CC, CX3C, and C.[@b3-cmar-11-1881] Recently, CXC chemokines and their receptors have aroused widespread attention in the field of tumor biology. Müller et al first reported the abnormal expression of C-C chemokine receptor type 7 (CCR7, a member of the C-C chemokine receptor family) in breast cancer.[@b4-cmar-11-1881] CCR7 is the major receptor for chemokine C ligand 19 (CCL19) and chemokine C ligand 21 (CCL21).[@b5-cmar-11-1881],[@b6-cmar-11-1881] It is mainly expressed on B cells, naive T cells, memory T cells, and mature dendritic cells. The binding between CCR7 and CCL19/CCL21 is vital for lymphocyte cell trafficking and homing to lymph nodes.[@b7-cmar-11-1881],[@b8-cmar-11-1881] CCR7 is also highly expressed by various malignant tumors, and contributes to biological processes such as tumor cell proliferation,[@b9-cmar-11-1881] invasion, metastasis,[@b10-cmar-11-1881] and angiogenesis.[@b11-cmar-11-1881] Thus, it may promote tumor progression and worsen patients' prognoses.

Elevated CCR7 expression has been associated with poor prognosis in patients with gastric cancer,[@b12-cmar-11-1881] esophageal squamous cell carcinoma (ESC),[@b13-cmar-11-1881] pancreatic cancer,[@b14-cmar-11-1881] and renal cell carcinoma.[@b15-cmar-11-1881] However, some studies have revealed no significant association between CCR7 expression and the outcomes of cancers like breast cancer[@b16-cmar-11-1881] and squamous cell carcinoma of the head and neck (SCCHN).[@b17-cmar-11-1881] In fact, in colorectal cancer[@b18-cmar-11-1881] and lung cancer,[@b19-cmar-11-1881] higher CCR7 expression has been found to predict better prognosis. Therefore, the prognostic value of CCR7 in cancer patients remains unclear. We conducted this systematic review and meta-analysis to further define the relationship between the expression of CCR7 and the survival outcomes of cancer patients.

Materials and methods
=====================

The guidelines of the PRISMA[@b20-cmar-11-1881] were followed in this meta-analysis.

Search strategy
---------------

We carefully search for literature in PubMed, Embase, and the Cochrane Library (last updated on January 15, 2018). Key terms used in the search were "CCR7", "C-C chemokine receptor type 7", "receptors", "cancer", "tumor", "neoplasm", "carcinoma", "survival", "outcome", "prognosis", and "prognostic". These key terms were combined by the Boolean operators "OR" and "AND". Advanced limitations were not imposed during the database search. We also manually screened the reference lists of the full-text studies to avoid the possible omission of applicable studies. Two authors (Zu G. and Luo B.) independently conducted the exhaustive research.

Inclusion and exclusion criteria
--------------------------------

Manuscripts were considered to be eligible for inclusion in this meta-analysis if they met the following criteria: 1) solid tumors were evaluated; 2) the expression of CCR7 was measured in tumor tissue; 3) the relationship between CCR7 levels and patients' survival outcomes was investigated; and 4) sufficient data were provided to determine the HR and 95% CI. Articles were excluded according to the following criteria: 1) case reports, reviews, letters, comments, conference abstracts, and experimental studies; 2) investigation of multiple factors rather than CCR7 alone; and 3) lack of key information on patients' survival outcomes, or lack of valid/sufficient data with which to estimate the HR and 95% CI. Two reviewers independently carried out the enrollment and exclusion based on the above criteria, and any disagreement was resolved by discussion.

Quality assessment
------------------

We evaluated the quality of each study according to the critical review checklist of the Dutch Cochrane Center proposed by the Meta-analysis of Observational Studies in Epidemiology group.[@b21-cmar-11-1881] The main standards were: 1) sufficient report on the study population and the cancer; 2) clear methods of study design; 3) explicit definition of outcome assessment; 4) detailed description of CCR7 measurement; and 5) sufficient period of follow-up. Studies that failed to meet these five standards were excluded.

Data extraction
---------------

Two researchers independently extracted valid data and related information from the eligible studies. Relevant parameters included the first author's surname, publication year, population origin, tumor type, tumor stage, sample number, detection method, follow-up period, sample collection time, cutoff values, and HRs of CCR7 expression for overall survival (OS), disease-free survival (DFS), progress-free survival (PFS), recurrence-free survival (RFS), and disease-specific survival (DSS), and the corresponding 95% CI and *P*-value. If a study reported the results of both univariate and multivariate analyses, the latter was selected because it accounts for confounding factors.

Statistical analysis
--------------------

CCR7 levels were defined based on the cutoff value provided in each article. We used the HRs and 95% CIs to calculate the pooled data, and thus evaluated the influence of elevated CCR7 levels on patients' prognoses. Statistical significance was defined as *P*\<0.05. The *Q* test and *I*^2^ statistic were used to evaluate heterogeneity. If *P*\<0.05 or *I*^2^\>50%, indicating the existence of heterogeneity, a random-effects model was used, while a fixed-effects model was used when *P*≥0.05 or *I*^2^≤50%. Sensitivity, subgroup, and meta-regression analyses were used to explore the potential sources of heterogeneity. Publication bias was analyzed with a funnel plot and Begg's and Egger's tests. We used Stata version 12.0 (StataCorp LP, College Station, TX, USA) to carry out all these analyses.

Results
=======

Study characteristics
---------------------

Using the search strategy described in the section "Materials and Methods", we initially collected 1,482 articles. After screening the titles, abstracts, and full texts of all the publications, we deemed 109 records eligible for full-text review. Of these, 79 full-text articles were excluded for having insufficient data. Thus, 30 qualified articles were enrolled in this meta-analysis[@b12-cmar-11-1881]--[@b19-cmar-11-1881],[@b22-cmar-11-1881]--[@b43-cmar-11-1881] ([Figure 1](#f1-cmar-11-1881){ref-type="fig"}).

The main characteristics of the included studies are summarized in [Table 1](#t1-cmar-11-1881){ref-type="table"}. The 3,413 patients included in these studies had been diagnosed with ESC, gastric cancer, breast cancer, non-small-cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, epithelial ovarian carcinoma, cervical cancer, etc. The studies included 3,237 patients with OS data, 406 patients with DFS data, 261 patients with RFS data, 192 patients with PFS data, and 203 patients with DSS data, who were from People's Republic of China, Japan, Germany, France, USA, UK, Austria, and Korea. Twenty-two studies (73%) reported on Asians, and eight studies (27%) reported on Caucasians. HRs and 95% CIs were reported directly in ten studies. CCR7 expression in tumor tissues was measured by immunohistochemistry in all 30 studies, although the cutoff values differed among these studies.

CCR7 and OS
-----------

OS data were reported in 28 of the studies.[@b12-cmar-11-1881]--[@b19-cmar-11-1881],[@b22-cmar-11-1881]--[@b41-cmar-11-1881] The detailed results of the meta-analysis are listed in [Table 2](#t2-cmar-11-1881){ref-type="table"}. As the meta-analysis results exhibited obvious heterogeneity (*I*^2^=67.8%; *P*=0.000), we used a random-effects model to calculate the pooled HR. Higher expression of CCR7 was associated with significantly poorer OS (pooled HR =1.79; 95% CI =1.49--2.16; *P*\<0.001) ([Figure 2](#f2-cmar-11-1881){ref-type="fig"}).

We then carried out subgroup analyses according to tumor type, tumor source, patient ethnicity, analysis type, and HR acquisition method; the detailed data are listed in [Table 2](#t2-cmar-11-1881){ref-type="table"}. Due to the obvious heterogeneity in each group, we used random-effects models to calculate the pooled HRs and 95% CIs. The forest plot of the study-specific pooled HRs and 95% CIs for OS according to tumor type is shown in [Figure 3](#f3-cmar-11-1881){ref-type="fig"}. Higher expression of CCR7 predicted poorer OS in patients with ESC (pooled HR =2.21; 95% CI =1.74--2.82; *P*\<0.001) and gastric cancer (pooled HR =1.99; 95% CI =1.58--2.51; *P*\<0.001), but was not significantly associated with OS in patients with breast cancer (pooled HR =1.24; 95% CI =0.94--1.62; *P*=0.123), lung cancer (pooled HR =0.89; 95% CI =0.29--2.71; *P*=0.841), or colorectal cancer (pooled HR =0.92; 95% CI =0.20--4.30; *P*=0.919). We also performed a subgroup analysis to evaluate the influence of the tumor source on OS. In patients with tumors of the digestive system and urogenital system, higher CCR7 levels were associated with poorer OS, with pooled HRs of 1.89 (95% CI =1.50--2.38; *P*\<0.001) and 2.42 (95% CI =1.87--3.13; *P*\<0.001), respectively ([Table 2](#t2-cmar-11-1881){ref-type="table"}). Remarkably, in the subgroup analysis according to ethnicity, higher CCR7 levels were associated with significantly poorer OS in Asian patients (pooled HR =1.89; 95% CI =1.56--2.29; *P*\<0.001), but not in Caucasian patients (pooled HR =1.53; 95% CI =0.89--2.62; *P*=0.121) ([Table 2](#t2-cmar-11-1881){ref-type="table"}).

CCR7 and DFS
------------

DFS data were reported by three studies for a total of 406 patients.[@b27-cmar-11-1881],[@b37-cmar-11-1881],[@b40-cmar-11-1881] As significant heterogeneity was found (*I*^2^=74.5%; *P*=0.020) in this meta-analysis, a random-effects model was used to calculate the pooled HR and 95% CI. The pooled HR was 1.69 (95% CI =0.79--3.61; *P*=0.175), which indicated that CCR7 expression did not correlate significantly with DFS ([Figure 4A](#f4-cmar-11-1881){ref-type="fig"}).

CCR7 and PFS
------------

Three studies comprising 192 patients provided valid data for PFS analysis.[@b15-cmar-11-1881],[@b17-cmar-11-1881],[@b41-cmar-11-1881] We used a fixed effects model to carry out the meta-analysis, as there was no obvious heterogeneity (*I*^2^=4.7%; *P*=0.350). Higher expression of CCR7 was associated with significantly poorer PFS (pooled HR =2.18; 95% CI =1.49--3.81; *P*\<0.001) ([Figure 4B](#f4-cmar-11-1881){ref-type="fig"}).

CCR7 and RFS
------------

Three articles including 261 patients provided relevant data for RFS analysis.[@b19-cmar-11-1881],[@b38-cmar-11-1881],[@b43-cmar-11-1881] As significant heterogeneity was detected (*I*^2^=88.4%; *P*=0.000), we used a random-effects model to calculate the pooled HR. The pooled HR was 1.29 (95% CI =0.48--3.44; *P*=0.618), which illustrated that higher CCR7 expression tended to portend poorer RFS, but no statistical significance was found ([Figure 4C](#f4-cmar-11-1881){ref-type="fig"}).

CCR7 and DSS
------------

For DSS, we performed a meta-analysis with two studies.[@b38-cmar-11-1881],[@b42-cmar-11-1881] A random effects model was used because heterogeneity was identified, and the pooled HR was 3.06 (95% CI =0.38--24.83; *P*=0.294). The detailed data are described in [Figure 4D](#f4-cmar-11-1881){ref-type="fig"}.

Heterogeneity analysis
----------------------

Due to the existence of significant heterogeneity, we performed further analyses to identify potential sources of heterogeneity. First, we conducted a meta-regression analysis, and found that the tumor type (*P*=0.117), patient ethnicity (*P*=0.349), analysis type (*P*=0.172), HR acquisition method (*P*=0.573), sample size (*P*=0.504), publication year (*P*=0.509), follow-up period (*P*=0.091), and cutoff value (*P*=0.444) contributed little to the heterogeneity. We also carried out subgroup analyses to explore the heterogeneity based on tumor type, tumor source, and patient ethnicity. The heterogeneity was still significant in each group ([Table 2](#t2-cmar-11-1881){ref-type="table"}), indicating that these factors could not solely explain the heterogeneity of the OS analysis.

To evaluate the stability and credibility of the heterogeneity, we performed a sensitivity analysis by omitting individual studies from the OS analysis using a fixed effects model. No individual study obviously impacted the combined HR ([Figure 5](#f5-cmar-11-1881){ref-type="fig"}). We also conducted sensitivity analyses to determine possible factors contributing to the heterogeneity of the DFS and RFS analyses. We found that no single study influenced the result pattern for DFS or RFS ([Figure 6A and B](#f6-cmar-11-1881){ref-type="fig"}).

Publication bias
----------------

We evaluated the possible publication bias of the included studies by using a funnel plot and Egger's test. The funnel plot of the OS analysis is shown in [Figure 7](#f7-cmar-11-1881){ref-type="fig"}. The*P*-value of Egger's regression intercept was 0.339, illustrating that there was no obvious publication bias in this meta-analysis. As the number of studies was not adequate to gain reliable results, we did not carry out publication bias analyses for the DFS, PFS, RFS, or DSS group.

Discussion
==========

CCR7, one of the seven transmembrane domain G protein-coupled receptors, is the common receptor for chemokines CCL19 and CCL21.[@b5-cmar-11-1881],[@b44-cmar-11-1881] They are naturally expressed by various immune cells and secondary lymphoid tissues. The binding of CCR7 to CCL19 and CCL21 induces the lymph-node homing of naive and regulatory T cells and dendritic cells, and promotes the metastasis of these cells to secondary lymphoid organs. The CCR7-CCL19/CCL21 axis regulates various adaptive immune functions, including regulatory and memory T-cell function, secondary lymphoid structure formation, thymocyte genesis, lymphocyte exudation in tumor tissue, high-affinity antigen-antibody immune responses, etc. This signaling axis is also crucial for maintaining the balance between immunity and tolerance.[@b45-cmar-11-1881]--[@b47-cmar-11-1881]

Due to the unique biological function of CCR7 in the immune system, the influence of it on the microenvironment of tumors has attracted widespread academic attention. It is abnormally expressed in a variety of tumors, and contributes to various malignant biological behaviors of tumors, especially, tumor lymph node metastasis. The CCR7-CCL19/CCL21 axis primarily promotes lymph node metastasis by recruiting tumor cells to the T-cell zone of the lymph nodes.[@b47-cmar-11-1881] The chemotactic interaction between CCR7 and CCL21 has been confirmed as the mechanism for lymph node metastasis in gastric cancer[@b35-cmar-11-1881] and esophageal cancer.[@b22-cmar-11-1881] CCR7/CCL21 is also widely recognized to induce lymph node metastasis by upregulating the expression of vascular endothelial growth factors C and D and further promoting lymphangiogenesis.[@b28-cmar-11-1881],[@b48-cmar-11-1881],[@b49-cmar-11-1881] Several recent studies have indicated that CCR7 is an important biological marker of tumor lymph node metastasis in many other cancers, including breast cancer,[@b50-cmar-11-1881] pancreatic cancer,[@b51-cmar-11-1881] bladder cancer,[@b52-cmar-11-1881] and head and neck squamous cell carcinoma.[@b10-cmar-11-1881]

CCR7 is also a key regulator of tumor invasion and distant metastasis. The main regulatory mechanisms are that 1) the CCR7-CCL21/CCL19 axis indirectly facilitates the epithelial-mesenchymal transition by regulating upstream gene expression;[@b36-cmar-11-1881],[@b53-cmar-11-1881] 2) the CCR7-CCL21/CCL19 axis promotes the expression of matrix metalloproteinases 2 and 9, markers of malignant tumor metastasis and invasion;[@b54-cmar-11-1881],[@b55-cmar-11-1881] and 3) CCR7 induces phosphatidylinositol-3 kinase/protein kinase B signaling,[@b56-cmar-11-1881] mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 signaling,[@b57-cmar-11-1881] and other related signaling pathways that promote tumor invasion and metastasis. An adequate blood supply is essential for tumor progression, and CCR7 also greatly stimulates tumor angiogenesis, mainly through the following mechanisms: 1) increasing the microvessel density, as part of the CCL21/CCR7 axis in tumor tissues;[@b11-cmar-11-1881] 2) enhancing the angiogenic capacity and inducing the proliferation and migration of human umbilical vein endothelial cells by activating the nuclear factor κB pathway;[@b58-cmar-11-1881] and 3) promoting the expression of vascular endothelial growth factor C in tumor tissues.[@b59-cmar-11-1881] In addition, CCR7 has been reported to prevent apoptosis and induce proliferation by promoting G2/M phase progression via the extracellular signal-regulated kinase pathway in human NSCLC.[@b9-cmar-11-1881],[@b60-cmar-11-1881] Moreover, CCR7 can downregulate interferon γ-induced inflammatory gene expression to weaken the host's antitumor immunity,[@b61-cmar-11-1881] thus facilitating cancer cell dissemination.[@b44-cmar-11-1881] Therefore, CCR7 overexpression in the tumor microenvironment is important for cancer progression and is associated with poor prognoses in cancer patients.

Although several studies have shown that CCR7 is a reliable indicator for the prognosis of tumor patients, the effect of CCR7 on the OS of tumor patients remains controversial. Different studies have had the opposite results, even regarding the OS of patients with the same tumor type, such as colorectal cancer[@b23-cmar-11-1881],[@b24-cmar-11-1881] or lung cancer.[@b19-cmar-11-1881],[@b28-cmar-11-1881] In addition, CCR7 has been reported to have no significant effect on OS in some tumor types, such as gastric cancer,[@b33-cmar-11-1881],[@b35-cmar-11-1881] breast cancer,[@b16-cmar-11-1881],[@b27-cmar-11-1881] and SCCHN.[@b17-cmar-11-1881] We found that the relationship between CCR7 and the prognosis of various tumors had not been systematically reviewed and further evaluated. Thus, we conducted this meta-analysis to provide a reliable evidence-based medical resource on the prognostic value of CCR7. In total, 30 studies encompassing 3,413 patients with 15 different types of tumors were enrolled in our meta-analysis, and five survival parameters (OS, PFS, RFS, DFS, and DSS) were analyzed. Through this meta-analysis, we provided strong evidence that higher expression of CCR7 is an independent prognostic indicator of poorer OS in patients with solid tumors. Elevated CCR7 levels were also associated with significantly worse PFS; however, there were not sufficient data to confirm that CCR7 was associated with DFS, RFS, or DSS.

To further evaluate the prognostic value of CCR7 in different tumors, we conducted subgroup analyses for OS. Due to the limited number of available articles, we did not carry out subgroup analyses for DFS, RFS, PFS, or DSS. We found that the upregulation of CCR7 significantly shortened the OS of patients with esophageal cancer and gastric cancer. In addition, overexpression of CCR7 tended to predict worse OS in breast cancer patients, but this impact was not notable. Remarkably, CCR7 had the opposite effect on patients with lung cancer and colorectal cancer, as higher CCR7 expression tended to be associated with a better prognosis; however, the results were not statistically significant. For these results, we cannot exclude the impact of insufficient sample sizes and limitations of the studies. We also found that CCR7 was a negative prognostic factor for OS in patients with digestive system and urogenital system tumors. In other systems, however, the relationship between CCR7 expression and tumor prognosis was not clear, suggesting that larger sample sizes and prospective studies are needed to further investigate the clinical prognostic value of CCR7 according to the tumor source.

We also explored the influence of CCR7 on the OS of patients from different ethnic backgrounds. Patients were categorized as Asian or Caucasian according to the country in which the study was conducted. Different combined HRs and *P*-values for OS were found in Asian and Caucasian patients: the association of high CCR7 expression with poor OS was more significant for Asian patients than for Caucasians. This suggests that racial differences may be an objective factor influencing the survival rate of tumor patients.

Although this meta-analysis confirmed the tumor prognostic value of CCR7, the limitations of this study should still be acknowledged. First, only 30 studies were enrolled in this meta-analysis, so there was a lack of relevant data for correlative and subgroup analyses. Second, the cutoff value for CCR7 expression was not uniform across the studies, which may reduce the effectiveness of CCR7 as a tumor prognostic marker. Third, some of the HR values were extracted from survival curves, which inevitably produced small statistical errors. Finally, this meta-analysis exhibited significant heterogeneity, which could be attributed to several factors, such as the tumor type, analysis method, sample source, cutoff value, follow-up period, and publication year.

In summary, our meta-analysis has suggested that in most solid malignancies, higher expression of CCR7 is associated with poorer prognoses of patients. Although elevated CCR7 expression tended to predict better prognoses in patients with lung cancer and colorectal cancer, these results need to be further confirmed due to their lack of statistical significance. Thus, we can conclude that CCR7 is a reliable, valuable prognostic marker in cancers. In view of the limitations of the current research, this conclusion should be interpreted cautiously. It will be necessary to design large, high-quality, multicenter, prospective clinical trials to confirm the potential value of CCR7 for the prognostic determination, clinical diagnosis, and treatment of tumor patients.
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###### 

Main characteristics of the included studies

  Study ID                                   Year   Country                      Cancer       Number   Tumor stage (I/II/III/IV)            Sample   Assay   Cutoff value              Multivariate analysis   Survival       HR   Follow-up (months)
  ------------------------------------------ ------ ---------------------------- ------------ -------- ------------------------------------ -------- ------- ------------------------- ----------------------- -------------- ---- -----------------------------
                                                                                                                                                                                                                                   
  Irino et al[@b13-cmar-11-1881]             2014   Japan                        ESC          105      52/53 (I--II/III)                    Tissue   IHC     IRS \>1                   No                      OS             SC   Up to 60
  Ding et al[@b22-cmar-11-1881]              2003   Japan                        ESC          96       50/46 (I--II/III--IV)                Tissue   IHC     IRS ≥8                    No                      OS             SC   Up to 100
  Shi et al[@b23-cmar-11-1881]               2015   People's Republic of China   ESC          153      I--III                               Tissue   IHC     IRS ≥8                    No                      OS             SC   Up to 60
  Liu et al[@b24-cmar-11-1881]               2013   People's Republic of China   ESC          184      I--III                               Tissue   IHC     IRS ≥3                    No                      OS             R    Median 48.6
  Song et al[@b25-cmar-11-1881]              2011   People's Republic of China   ESC          174      122/62 (I--II/III)                   Tissue   IHC     \>10% of cells stained    Yes                     OS             SC   Up to 33
  Liu et al[@b26-cmar-11-1881]               2010   People's Republic of China   Breast       200      177/23 (I--II/III--IV)               Tissue   IHC     IRS ≥6                    No                      OS             SC   Median 88
  Andre et al[@b27-cmar-11-1881]             2006   France                       Breast       142      93/49 (I--II/III)                    Tissue   IHC     IRS ≥3                    Yes                     OS, DFS        R    Median 156
  Cabioglu et al[@b16-cmar-11-1881]          2007   USA                          IBC          44       44 (III)                             Tissue   IHC     \>50% of cells stained    No                      OS             SC   Median 46.5
  Sun et al[@b28-cmar-11-1881]               2015   People's Republic of China   NSCLC        90       39/51 (I--II/III--IV)                Tissue   IHC     IRS ≥6                    No                      OS             SC   Median 32.5
  Itakura et al[@b19-cmar-11-1881]           2013   Japan                        Lung         120      69/51 (I--II/III--IV)                Tissue   IHC     Median                    No                      OS, RFS        R    NR
  Günther et al[@b29-cmar-11-1881]           2005   Germany                      Colorectal   99       40/59 (I--II/III--IV)                Tissue   IHC     IRS ≥1                    No                      OS             R    Median 64
  Schimanski et al[@b18-cmar-11-1881]        2005   Germany                      Colorectal   96       46/50 (I--II/III--IV)                Tissue   IHC     IRS ≥2                    No                      OS             SC   Up to 36
  Zhou et al[@b12-cmar-11-1881]              2013   People's Republic of China   Gastric      133      50/83 (T1--2/T3--4)                  Tissue   IHC     Mean                      Yes                     OS             SC   Median 43
  Ishigami et al[@b30-cmar-11-1881]          2007   Japan                        Gastric      224      120/124 (I--II/III--IV)              Tissue   IHC     Mean                      No                      OS             R    Up to 60
  Ma et al[@b31-cmar-11-1881]                2015   People's Republic of China   Gastric      122      61/61 (0--II/III--IV)                Tissue   IHC     \>50% of cells stained    No                      OS             R    Up to 125
  Zhang et al[@b32-cmar-11-1881]             2015   People's Republic of China   Gastric      90       29/61 (I--II/III--IV)                Tissue   IHC     \>50% of cells stained    Yes                     OS             R    Median 25
  Deguchi et al[@b33-cmar-11-1881]           2010   Japan                        Gastric      72       46/36 (T1--2/T3--4)                  Tissue   IHC     NR                        No                      OS             SC   Up to 120
  Kwak et al[@b34-cmar-11-1881]              2005   Korea                        Gastric      307      190/117 (I--II/III--IV)              Tissue   IHC     Moderate staining         No                      OS             SC   Median 67
  Mashino et al[@b35-cmar-11-1881]           2002   Japan                        Gastric      64       44/20 (I--IIIa/IIIb--IV)             Tissue   IHC     Strongly/weakly stained   No                      OS             SC   Median 21.5
  Xia et al[@b15-cmar-11-1881]               2017   People's Republic of China   MRCC         110      51/59 (I--III/IV)                    Tissue   IHC     NR                        Yes                     OS, PFS        R    Median 23.5 (OS), 9.8 (PFS)
  Cheng et al[@b36-cmar-11-1881]             2015   People's Republic of China   EOC          30       12/18 (I--II/III--IV)                Tissue   IHC     IRS ≥4                    Yes                     OS             SC   Median 32
  Kodama et al[@b37-cmar-11-1881]            2007   Japan                        Cervical     174      92/82 (IB--IIB)                      Tissue   IHC     \>50% of cells stained    No                      OS, DFS        SC   Median 56.5
  Pitkin et al[@b38-cmar-11-1881]            2007   UK                           Tonsillar    84       36/48 (I--III/IV)                    Tissue   IHC     \>33% of cells stained    No                      OS, RFS, DSS   SC   Median 33
  Xia et al[@b39-cmar-11-1881]               2015   People's Republic of China   OSSC         60       36/24 (I--II/III--IV)                Tissue   IHC     Median                    Yes                     OS             SC   Up to 80
  Tsuzuki et al[@b40-cmar-11-1881]           2006   Japan                        OOSCC        90       29/61 (I--II/III--IV)                Tissue   IHC     \>33% of cells stained    Yes                     OS, DFS        SC   30--60
  Mburu et al[@b17-cmar-11-1881]             2012   USA                          SCCHN        47       13/30 (I--II/III--IV) 4 (unstaged)   Tissue   IHC     Median                    Yes                     OS, PFS        R    Up to 120
  Kühnelt-Leddihn et al[@b41-cmar-11-1881]   2012   Austria                      PCM          38       NR                                   Tissue   IHC     NR                        No                      OS, PFS        SC   Up to 120 (OS), 60 (PFS)
  Nakata et al[@b14-cmar-11-1881]            2008   Japan                        Pancreatic   89       82/7 (I--II/III--IV)                 Tissue   IHC     Strongly/weakly stained   Yes                     OS             R    Up to 120
  von Hardenberg et al[@b42-cmar-11-1881]    2014   Germany                      UCB          119      45/74 (T1--2/T3--4)                  Tissue   IHC     IRS ≥2                    No                      DSS            R    Median 31
  Zhou[@b43-cmar-11-1881]                    2013   People's Republic of China   UCB          57       23/34 (T1--2/T3--4)                  Tissue   IHC     IRS ≥4                    No                      RFS            SC   Median 43

**Abbreviations:** DFS, disease-free survival; DSS, disease-specific survival; EOC, epithelial ovarian carcinoma; ESC, esophageal squamous cell carcinoma; IBC, inflammatory breast cancer; IHC, immunohistochemistry; IRS, immunoreactivity score; MRCC, metastatic renal cell carcinoma; NR, not reported; NSCLC, non-small-cell lung cancer; OOSCC, oral and oropharyngeal squamous cell carcinoma; OS, overall survival; OSSC, oral squamous cell carcinoma; PCM, primary cutaneous melanoma; PFS, progress-free survival; R, reported; RFS, recurrence-free survival; SC, survival curve; SCCHN, squamous cell carcinoma of the head and neck; UCB, carcinoma of the bladder.

###### 

Pooled HRs and 95% CIs for OS according to subgroup

  Subgroup analysis       No. of patients   No. of studies   Random-effects model   Heterogeneity          
  ----------------------- ----------------- ---------------- ---------------------- --------------- ------ -------
                                                                                                           
  OS                      3,237             28               1.79 (1.49--2.16)      \<0.001         67.8   0.000
  Ethnicity                                                                                                
   Asian                  2,687             21               1.89 (1.56--2.29)      \<0.001         63.0   0.000
   Caucasian              550               7                1.53 (0.89--2.62)      0.121           77.0   0.000
  Tumor type                                                                                               
   ESC                    712               5                2.21 (1.74--2.82)      \<0.001         0      0.496
   Gastric                1,012             7                1.99 (1.58--2.51)      \<0.001         0      0.954
   Breast                 386               3                1.24 (0.94--1.62)      0.123           29.9   0.240
   Lung                   210               2                0.89 (0.29--2.71)      0.841           92.2   0.000
   Colorectal             195               2                0.92 (0.20--4.30)      0.919           92.7   0.000
   Other                  722               9                2.38 (1.94--2.93)      \<0.001         0      0.990
  Tumor source                                                                                             
   Digestive system       2,008             15               1.89 (1.50--2.38)      \<0.001         55.1   0.005
   Urogenital system      314               3                2.42 (1.87--3.13)      \<0.001         0      0.766
   Other                  915               10               1.50 (1.09--2.06)      0.012           68.9   0.001
  Analysis type                                                                                            
   Multivariate           965               10               2.12 (1.65--2.73)      \<0.001         40     0.091
   Univariate             2,272             18               1.63 (1.30--2.06)      \<0.001         70.8   0.000
  HR acquisition method                                                                                    
   Reported               1,227             10               1.64 (1.12--2.41)      0.012           75.0   0.000
   Extrapolated           2,010             18               1.88 (1.52--2.33)      \<0.001         64.0   0.000

**Abbreviations:** ESC, esophageal squamous cell carcinoma; OS, overall survival.

[^1]: These authors contributed equally to this work
